MMP-7蛋白在肺癌患者和正常人外周血中的表达水平及临床意义

背景与目的基质金属蛋白酶7(matrix metalloproteinase7,MMP-7)又称基质溶解素,是MMPs家族成员之一,本研究旨在检测MMP-7在肺癌患者和正常人外周血血浆中的蛋白水平,并探讨其临床意义。方法采用酶联接免疫吸附试验(enzyme-linked immunosorbnent assay,ELISA)检测114例肺癌患者和100名正常人外周血血浆标本中的MMP-7浓度。结果肺癌患者外周血血浆中的MMP-7蛋白浓度(n=114,median=0.72ng/mL)明显高于正常人外周血血浆中的MMP-7蛋白浓度(n=100,median=0.30ng/mL,P<0.001),当cuto值为0.56ng/mL时,MMP-7检测肺癌的敏感性为62.3%,特异性为76.0%。但是,肺癌患者外周血血浆中MMP-7的蛋白水平与患者的年龄、性别、吸烟史、肿瘤大小、病理类型、淋巴结转移及分期均无关(P>0.05)。结论外周血血浆中MMP-7可以作为辅助肺癌诊断的一种肿瘤标志物,但其与肺癌的各项临床参数之间无明显联系,需要进一步扩大样本进行分析。     

非霍奇金淋巴瘤D-二聚体的表达及临床相关性研究

目的:研究非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)患者血浆D-二聚体(D-dimer)水平与NHL的临床病理学参数的关系。方法:ELISA法检测36例NHL患者血浆D-dimer的水平。结果:NHL患者D-dimer水平为(684.19±463.67)ng/mL,较对照组的(181.67±128.93)ng/mL显著升高(P <0.01)。侵袭性NHL D-dimer水平为(926.83±510.47)ng/mL,高于惰性NHL患者的(502.21±331.68)ng/mL(P<0.01)。LDH异常的NHL患者D-dimer水平为(463.89±109.22)ng/mL,高于LDH正常者的(365.39±311.93)ng/mL,差异具有显著性(P <0.01)。结论:NHL患者D-dimer血浆水平反映淋巴瘤患者的病情演变,有助于选择化疗方案和判断预后。     

非小细胞肺癌患者血清MMP-9表达及siRNA靶向抑制A549细胞侵袭与转移的研究

目的:探讨非小细胞肺癌患者血清中MMP-9表达与肿瘤转移的关系;MMP-9siRNA对肺腺癌细胞系A549中MMP-9表达及细胞侵袭与转移抑制作用的影响。方法:ELISA法检测32例非小细胞肺癌(NSCLC)患者及20名健康者空腹血清MMP-9浓度,同时设计合成针对MMP-9的特异性siRNA,采用oligofectamine转染A549细胞,RT-PCR法检测转染细胞后MMP-9mRNA的表达,Transwell实验检测细胞侵袭情况。结果:NSCLC患者血清中MMP-9浓度〔(63.44±7.84)ng/mL〕比正常对照组〔(21.57±3.29)ng/mL〕明显升高(P<0.01),且浓度随病理分期增加而增强〔Ⅰ/Ⅱ:(45.40±5.30)ng/mL,Ⅲ/Ⅳ:(89.80±5.02)ng/mL,P<0.01〕,发生淋巴结转移的患者血清MMP-9浓度〔(82.26±5.09)ng/mL〕明显高于未发生淋巴结转移〔(35.92±4.68)ng/mL〕的患者P<0.01;RT-PCR法显示,转染MMP-9siRNA后,细胞中MMP-9mRNA表达较阴性对照组和空白组明显降低,P<0.05。RNA干扰MMP-9基因后A549细胞的侵袭能力也有明显下降,P<0.01。结论:MMP-9可作为NSCLC患者有无发生浸润转移的良好预测指标,靶向MMP-9的siRNA不仅能特异性的降低MMP-9mRNA及蛋白的表达,且能抑制人A549细胞的侵袭和迁移。     

布洛芬抑制人肝癌细胞BEL-7402生长及机制的初步研究

背景与目的：近来发现,临床上常用的非甾体类抗炎药(non-steroidal anti-inflammatory drugs,NSAIDs)可以降低多种癌症的发病率。布洛芬(ibuprofen)作为一种常用的NSAIDs,对肝癌是否具有抑制作用,国内外鲜有报道。本研究初步探讨布洛芬抑制肝癌细胞BEL-7402的作用,并研究其相关机制。方法：肝癌细胞BEL-7402分为对照组和不同浓度布洛芬处理组,药物处理0、24、48和72 h后用MTT法检测各组细胞增殖抑制率;流式细胞术检测各组细胞的周期分布;细胞分析仪检测各组细胞活力及细胞凋亡;蛋白[质]印迹(Western blot)检测各组细胞增殖性核抗原(PCNA)、细胞周期蛋白(Cyclin D1)、B细胞淋巴瘤/白血病-2 (Bcl-2)和环氧合酶-2(COX-2)蛋白的表达;ELISA法检测细胞培养上清液中前列腺素E₂(PGE₂)蛋白表达水平。结果：布洛芬组中BEL-7402细胞增殖受到抑制,且抑制作用呈时间和剂量依赖性(P<0.05)。2.0 mmol/L布洛芬组48 h细胞活力明显低于对照组［(47.87±5.23)% vs (88.93±5.49)%］,G₀/G₁期细胞比例明显高于对照组［(80.04±3.61)%vs (62.36±8.33)%］,细胞早期凋亡率明显高于对照组［(36.65±10.07)% vs (9.81±6.80)%］,差异有统计学意义(P<0.05)。布洛芬作用于细胞48 h后,PCNA、Cyclin D1、Bcl-2以及COX-2蛋白表达与对照组相比显著减少(P<0.05);细胞培养上清液中PGE₂蛋白表达量与对照组［(23.98±4.89) ng/L vs (68.70±9.43) ng/L］相比,显著降低(P<0.01)。结论：布洛芬能够抑制肝癌细胞BEL-7402增殖与活力,阻滞细胞周期,促进细胞凋亡,其作用机制可能与抑制COX-2及PGE₂表达有关。     

胃癌组织MMP-9基因及蛋白表达与肿瘤临床病理关系研究

目的:研究胃癌患者基质金属蛋白酶-9表达与肿瘤临床病理参数之间相关性。方法:应用酶联免疫吸附(ELISA)方法检测术前外周血清及胃液中MMP-9蛋白水平。结果:胃癌组、对照组血清中金属蛋白酶平均水平分别为406.03±257.18 ng/m l、167.35±54.04 ng/m l,(P<0.01);TNM晚期、淋巴结转移阳性者术前外周血清蛋白含量显著高于TNM早期、淋巴结转移阴性者(P<0.01)。胃癌组术前胃液中MMP-9蛋白平均水平为77.59±191.97ng/m l,对照组胃液中MMP-9蛋白平均水平为0.81±2.39ng/m l,(P<0.01)。肿瘤侵犯至浆膜层、TNM晚期、淋巴结转移阳性者蛋白含量显著高于肿瘤未侵犯至浆膜层、TNM早期、淋巴结转移阴性者(P<0.01)。结论:检测胃癌患者术前胃液中血清中蛋白酶水平能反映肿瘤进展。     

血清标志联合检测对胃肠胰神经内分泌肿瘤诊断价值分析

目的:探讨癌胚抗原(carcinoembryonic antigen,CEA)、骨桥蛋白(osteopontin,OPN)、肿瘤抗原19-9(cancer antigens 199,CA19-9)和神经元特异性烯醇化酶(neural specificity enol,NSE)血清水平检测在胃肠胰神经内分泌肿瘤(gastroenteropancreatic neuroendocrine neoplasm,GEP-NEN)诊断和治疗中的应用。方法:检测56例GEP-NEN患者术前及术后1个月CEA、OPN、CA19-9和NSE血清水平,并与良性肿瘤组(30例)和健康对照组(30名)比较,分析其在GEPNEN诊断和疗效监测中的价值。结果:GEP-NEN组血清CEA、OPN、CA19-9和NSE水平分别为(39.22±21.21)ng/mL、(156.51±42.23)ng/mL、(58.13±13.42)U/mL和(37.21±12.78)ng/mL,明显高于良性肿瘤组的(2.71±2.01)ng/mL、(30.12±8.91)ng/mL、(13.12±6.23)U/mL和(10.47±4.87)ng/mL及健康对照组的(2.57±1.43)ng/mL、(28.89±7.92)ng/mL、(12.72±6.74)U/mL和(9.11±3.19)ng/mL,P值均<0.01;良性肿瘤组与健康对照组比较,差异无统计学意义,P>0.05。GEP-NEN患者术后1个月血清CEA、OPN、CA19-9和NSE水平分别为(21.34±11.34)ng/mL、(89.27±21.78)ng/mL、(38.27±7.23)U/mL和(22.41±7.28)ng/mL,明显低于术前(39.22±21.21)ng/mL、(156.51±42.23)ng/mL、(58.13±13.42)U/mL和(37.21±12.78)ng/mL,差异有统计学意义,P<0.01。NEN血清CEA、OPN、CA19-9和NSE水平与患者年龄、性别和肿瘤部位无关,P>0.05;与肿瘤组织学类型、分级、分期和淋巴结转移有关,P<0.05。CEA、CA19-9和NSE联合检测,可提高敏感性达96.43%,特异性85.00%,准确性90.52%,阴性预测值96.23%,再联合OPN可略提高敏感性,但降低特异性不能提高诊断的准确率。结论:血清CEA、OPN、CA19-9和NSE检测可作为GEP-NEN早期诊断和疗效监测指标,CEA+CA19-9+NSE联合检测敏感性、准确性和阴性预测值较高。     

纳米硫化镉与硫化镉雄性生殖毒性及相关机制的研究

目的： 探讨纳米硫化镉(Nano-CdS)和硫化镉(CdS)的雄性生殖毒性作用机制并比较其生殖毒性效应。方法：将36只SPF级雄性ICR小鼠随机分为对照组、Nano-CdS组和CdS组,每组各12只。两个染毒组经口灌胃染毒,每天灌胃1次,染毒剂量均为50 mg/kg,对照组给予等体积的生理盐水,连续45 d。采用石墨炉原子吸收光谱法检测小鼠睾丸组织中镉元素积累水平,显微镜下观察小鼠精子畸形率,采用酶联免疫吸附法(ELISA)检测小鼠血清睾酮水平,采用荧光实时定量PCR检测P450scc和P450-17α mRNA表达水平。结果：镉元素含量分析结果显示,Nano-CdS和CdS组小鼠睾丸组织中的镉元素含量分别为(425.46±73.89)和(183.59±32.46) ng/g,均高于对照组的(80.18±13.29) ng/g (P<0.05)。精子畸形率检测结果显示,CdS组小鼠(2.28%)显著高于对照组(1.48%) (P<0.05),Nano-CdS组(1.73%)也有所升高。ELISA检测结果显示,Nano-CdS和CdS组小鼠血清睾酮浓度分别为(12.31± 1.10)和(15.88±5.41)ng/dL,均明显低于对照组的(68.41±11.36) ng/dL(P<0.05)。荧光实时定量PCR检测结果显示,Nano-CdS和CdS组P450scc mRNA的表达水平分别为0.50±0.11和0.84±0.48;P450-17α mRNA的表达水平分别为0.51±0.13和0.72±0.06,除CdS组P450scc mRNA表达水平外,其他各组均明显低于对照组(P<0.05)。结论：Nano-CdS和CdS均能导致小鼠睾丸中镉元素的积累,一定程度上诱导精子畸形率的升高,并能显著降低血清睾酮水平以及抑制P450scc和P450-17α mRNA的表达水平。     

血清肿瘤标志物在肺癌辅助诊断中的应用

目的探讨5种血清肿瘤标志物在肺癌辅助诊断中的应用价值,并选择最理想的血清肿瘤标志物组合。方法应用酶联免疫吸附实验(ELISA)检测170例肺癌患者、50例健康人和60例肺部良性疾病患者血清中神经元特异性烯醇化酶(NSE)、胃泌素释放肽前体(pro GRP)、细胞角蛋白19(CYFRA211)、p53抗体和癌胚抗原(CEA)的水平含量。结果肺癌患者的5种血清肿瘤标志物水平均明显高于健康人组和肺部良性疾病组,差异有统计学意义(P<0.01)。NSE、pro GRP在小细胞肺癌中的水平明显高于其他类型的肺癌(P<0.01),CYFRA211在鳞癌中的水平明显高于其他类型的肺癌(P<0.01)。p53抗体的特异性为100%,NSE、pro GRP对小细胞肺癌检测的敏感性明显高于其他类型的肺癌(P<0.01),CYFRA211对鳞癌检测的敏感性明显高于其他类型的肺癌(P<0.01)。5种血清肿瘤标志物经组合后,敏感性明显高于任一单项肿瘤标志物(P<0.01)。结论5种血清肿瘤标志物对于肺癌的辅助诊断有一定的临床意义。NSE、pro GRP二者可作为联合检测小细胞肺癌的首选标志物,CYFRA211、CEA和p53抗体三者可作为联合检测非小细胞肺癌的首选标志物。p53抗体对肺癌的辅助诊断有很高的特异性,CYFRA211对鳞癌的辅助诊断有一定的作用。     

调强放疗联合化疗对晚期非小细胞肺癌血清三种因子表达变化的队列研究

目的 探究调强放疗联合化疗对晚期非小细胞肺癌(NSCLC)患者血清细胞增殖抗原(PCNA)、肿瘤特异性生长因子(TSGF)、可溶性E-钙黏蛋白(SE-CAD)表达变化及与预后的关系。方法 选取2016-2018年南京医科大学附属淮安第一医院收治的晚期NSCLC患者 84例(ⅢA、ⅢB、Ⅳ期分别为29、30、25例),均给予调强放疗联合化疗。检测对比不同TNM分期、治疗前后血清PCNA、TSGF、SE-CAD水平,并比较不同疗效患者血清PCNA、TSGF、SE-CAD水平。采用Logistic法分析血清PCNA、TSGF、SE-CAD水平与疗效关系。Kaplan-Meier法生存分析。结果 Ⅳ期患者疗前血清PCNA、TSGF、SE-CAD水平高于 ⅢB和 ⅢA期[(584.11±60.25) pg/ml∶(531.06±51.37) pg/ml和(477.54±46.49) pg/ml、(96.13±7.54) U/ml∶(88.52±5.91) U/ml和(82.41±5.0) U/ml、(3.02±0.26) ng/ml∶(2.87±0.22) ng/ml和(2.71±0.15) ng/ml,均 P<0.05],ⅢB期高于 ⅢA期(均 P<0.05)。疗后血清PCNA、TSGF、SE-CAD水平低于疗前水平[(396.11±50.23) pg/ml∶(528.37±75.09) pg/ml、(74.81±4.72) U/ml∶(88.68±6.13) U/ml、(1.92±0.24) ng/ml∶(2.86±0.31) ng/ml,均 P<0.05]。疗后18个月生存患者PCNA、TSGF、SE-CAD水平低于死亡患者[(332.51±54.32) pg/ml∶(444.92±60.07) pg/ml、(70.59±6.20) U/ml∶(78.05±8.44) U/ml、(1.71±0.24) ng/ml∶(2.08±0.27) ng/ml,均 P<0.05]。血清PCNA、TSGF、SE-CAD水平与预后显著相关(均 P<0.05)。84例NSCLC患者疗后客观缓解率为29%(24/84)。疗后血清血清PCNA、TSGF、SE-CAD高表达组生存曲线低于低表达组(均 P<0.05)。结论 血清PCNA、TSGF、SE-CAD水平在晚期NSCLC患者中呈高表达,与临床分期、预后密切相关,且有助于预测生存状况。     

Alu-qPCR检测游离DNA长度在肺结节良恶性鉴别中的应用

目的:评价Alu-qPCR检测肺结节患者血浆cfDNA浓度及凋亡指数在鉴别结节良、恶性中的应用价值。方法:收集纯化70例肺部结节患者血浆,检测cfDNA浓度、凋亡指数及肿瘤蛋白标记物,并分析上述指标与患者临床特征的关系。结果:非小细胞肺癌组与肺部良性结节组血浆短片段cfDNA平均含量为129.86、91.12 ng/mL(P>0.05),长片段cfDNA平均含量为33.95、38.24 ng/mL(P<0.05)。平均凋亡指数9.44、5.35(P<0.05)。长片段cfDNA浓度、DNA凋亡指数可作为潜在诊断指标,对应临界值:6.22、29.50 ng/mL,灵敏度:0.63、0.74,特异度:0.77、0.85。良、恶性结节患者肿瘤标记物水平统计学差异不显著。结论:cfDNA检测在肺结节性质判断方面具有潜在应用价值,可为术前结节性质判定提供参考。肿瘤标记物在监测肿瘤转移、复发中意义较大。     

血清骨桥蛋白检测对肝癌诊断意义初步分析

目的:探索血清骨桥蛋白(OPN)作为肝细胞癌(HCC)生物标志的应用价值.方法:应用ELISA法检测70例HCC患者、65例慢性肝脏疾病(CLD)患者及65名健康人血清OPN、甲胎蛋白(Alpha- fetoprotein,AFP)浓度.结果:HCC组血清OPN浓度(中位数975 ng/mL,范围131～5 920 ng/mL)明显高于CLD组(352 ng/mL,18～1 875 ng/mL,P＜0.001)或健康人组(103 ng/mL,8～984 ng/mL,P＜0.001).在HCC组,血清OPN浓度随着Child-Pugh分级(F=8.053,P=0.001)及肿瘤分期(P-0.01)的升高而显著升高,且血清OPN浓度与肿瘤包膜的完整性明显相关(P=0.001).OPN诊断HCC的敏感度、特异度及临界值分别为87.1％、75.4％和642.5 ng/mL.OPN曲线下面积(0.895士0.028)比AFP(0.817±0.04)大(P＜0.01),这提示OPN有优越的诊断效能.结论:血浆中OPN浓度可以作为诊断HCC潜在的参考分子指标之一.     

胃癌患者血清可溶性E-选择素检测的临床意义

目的:探讨血清可溶性E-选择素（sE-selectin ）检测在胃癌诊治中的临床意义。方法:采用ELISA 法检测200 例胃癌患者、45例胃良性疾病患者和40例健康体检者血清中的可溶性E-选择素水平,比较其中140 例胃癌患者手术前后血清可溶性E-选择素水平的变化,并对胃癌患者血清可溶性E-选择素、CEA 、CA199 和CA724 的阳性率进行比较。结果:胃癌组血清可溶性E-选择素表达水平为69.12± 18.19ng/mL,与正常对照组（15.85± 5.27ng/mL）及良性疾病组（19.47±7.88ng/mL）比较,差异性具有统计学意义（P<0.01）。 血清可溶性E-选择素阳性表达与肿瘤部位及组织学分型无明显相关（P>0.05）,但与病理分期及肝转移呈正相关（P<0.05,P<0.01）。胃癌患者手术后血清可溶性E-选择素水平明显下降。胃癌患者血清可溶性E-选择素阳性率远远高于其他消化道肿瘤标物（CEA 、CA199、CA724）,P<0.01。结论:可溶性E-选择素有可能成为胃癌早期辅助诊断、预测复发转移及评估预后有价值的肿瘤标记物。      

Serum BMP-2 Up-regulation as an Indicator of Poor Survival in Advanced Non-small Cell Lung Cancer Patients

Purpose: High levels of bone morphogenetic protein (BMPs) have been reported in patients with lung cancer.This study was conducted to assess correlations between serum BMP-2 levels and prognostic outcome in patientswith non-small-cell lung cancer (NSCLC). Methods: Blood samples from 84 patients with advanced NSCLCand 42 healthy controls were analyzed and quantitated for serum BMP-2 levels before and after two cycles ofchemotherapy using a commercially available ELISA kit. Results: The median level of BMP-2 was 146.9 pg/ml in patients with NSCLC vs. 87.7 pg/ml in healthy controls (P<0.01). A significant correlation was observedbetween pretreatment serum BMP-2 level and ECOG PS, disease stage and number of organs with metastases(P<0.05). Serum BMP-2 level decreased significantly in patients who achieved objective response after twocycles of chemotherapy. Multivariate analysis showed that increased BMP-2 level and advanced clinical stagewere significantly correlated with poor prognosis. Conclusion: Thes erum BMP-2 level is positively correlatedwith clinical stage, ECOG PS and metastatic burden and may serve as an independent negative predictor forprognosis. Decreased BMP-2 after chemotherapy could be a reliable marker for efficacy of treatment.     

转录因子T-bet和GATA-3在食管癌患者外周血单个核细胞中的表达及其与患者免疫状态的关系

目的 观察转录因子T-bet和GATA-3在食管痛患者外周血单个核细胞(PBMC)中的表达,并探讨其与患者免疫状态的关系.方法 采用逆转录-荧光定量-聚合酶链反应(RT-FQ-PCR)检测60例食管癌患者和30例健康对照者PBMC中T-bet和GATA-3的mRNA表达水平,采用酶联免疫吸附法(ELISA法)检测血浆中干扰素γ(IFN-γ)和白细胞介素4(IL-4)的水平.结果 与健康对照组相比,食管癌患者T-bet mRNA表达明显降低(Ⅰ、Ⅱ期食管癌组为0.27±0.05,Ⅲ、Ⅳ期食管癌组为0.12±0.02),GATA-3 mRNA表达明显升高(Ⅰ、Ⅱ期食管癌组为0.45±0.06,Ⅲ、Ⅳ期食管癌组为0.55±0.03),IFN-γ表达明显降低[Ⅰ、Ⅱ期食管癌组为(12.12±1.48)ng/L,Ⅲ、Ⅳ期食管癌组为(8.44±0.90)ng/L],IL-4表达明显升高[Ⅰ、Ⅱ期食管癌组为(18.64±0.77)ng/L,Ⅲ、Ⅳ期食管癌组为(25.28±2.02)ns/L],Ⅰ、Ⅱ期食管癌组与Ⅲ、Ⅳ期食管癌组间差异无统计学意义(均P>0.05).IFN-γ水平与T-bet mRNA表达呈正相关(r=0.79,P<0.05),IL-4与GATA3 mRNA表达呈正相关(r=0.43,P<0.05).结论 食管癌患者外周血中T-bet表达降低,GATA-3表达升高,Th1和Th2平筏被打破,Th2占优势.T-bet和GATA-3参与了Th1和Th2平衡的调控.     

Kinin-generating Cascade in Advanced Cancer Patients and in vitro Study

The role of the bradykinin-generating system in the pathogenesis of cancer was explored by simultaneously measuring plasma prekallikrein (PK), the precursor of kallikrein, which is the major enzyme responsible for kinin generation, and plasma kininogens (KNG), which are precursors of kinin, in patients with various cancers. The mean value of plasma PK in healthy volunteers was 2.5 ± 0.5 (mean ± SD) units/mg plasma protein and that in cancer patients (all stage IV) was 1.7 ± 0.7 units/ mg plasma protein. The mean value of plasma KNG in healthy volunteers was 12.5 ± 2.0 ng kinin equivalents/mg plasma protein and that in cancer patients was 10.9 ± 2,8 ng. These data showed that plasma PK and plasma KNG values were significantly lower in cancer patients compared with healthy volunteers ( P < 0.0005 for PK; 0.0005 < P < 0.005 for KNG; n = 28 for healthy subjects; n = 29 for cancer patients). These data appear to indicate that conversion of PK to kallikrein would probably occur with concomitant consumption of KNG by newly generated kallikrein for kinin generation in cancer patients. Early stage cancer patients showed little difference from healthy volunteers. For the in vitro study, activation of purified Hageman factor (HP) and PK was examined by using cancer cell lines and virus-transformed cells that produced plasminogen activator (PA) at a high rate. Both HF and PK were activated in the presence of plasminogen. Diploid cell lines and primary fibroblasts, which did not produce PA, activated neither HF nor PK. Taking all these data together, we conclude that kinin generation does occur in the plasma of patients with advanced cancer, and that one of the initiation mechanisms of the kinin-generating cascade appears to be mediated by plasmin and to depend on cancer cell-derived PA activity.     

肺癌患者运动心肺功能的特点及影响因素的观察

目的 探讨肺癌患者运动心肺功能的特点及其可能的影响因素。方法 对20例健康者和198例肺癌患者行静息肺功能、心电图和运动心肺功能测定。结果 1.与健康组相比，静息肺通气功能正常的肺癌患者VO2％P、VO2／kg、AT、VO2／HR％、VE、VT／VC显著降低，而BR显著增加（P＜0.05或P＜0.01）。2.在静息肺通气功能正常的情况下，周围型和中心型组间各指标均无显著性差异。3.肺癌患者心肺功能与TNM分期有密切关系（P＜0.05或P＜0.01）。4.血管侵犯组W％、VO2％P、AT、VO2／HR％较无血管侵犯组显著降低（P＜0.05或P＜0.01）。结论 肺癌患者在静息肺功能正常的情况下，存在着运动通气受限。其运动心肺功能的减退与肺癌的TNM分期和肺癌侵犯大血管有关。     

3.0T MR动脉自旋标记技术对早期原发性肝癌的诊断价值

目的 探讨3.0T MR动脉自旋标记(arterial spin labeling,ASL)技术诊断早期原发性肝癌的价值。方法 对经肝脏穿刺活检病理证实的22例早期原发性肝癌患者(早期肝癌组)及20名健康志愿者(健康对照组)行3D-假连ASL(pseudo-CASL,pCASL)序列扫描,比较两组平均、最高及最低血流量(blood flow,BF),并采用受试者工作特征曲线(receiver operating characteristic curve,ROC)分析其诊断效能。结果 早期肝癌组肿瘤组织的平均、最高及最低BF值均较健康对照组肝组织增高[(108.69±27.32) mL/(100g·min) vs (78.85±34.89) mL/(100g·min),(138.59±61.61) mL/(100g·min) vs (99.32±50.01) mL/(100g·min),(70.18±12.01) mL/(100g·min) vs (48.63±11.77) mL/(100g·min),P<0.05]。平均、最高及最低BF值鉴别早期肝癌组肿瘤组织与健康对照组肝组织的ROC曲线下面积分别为0.736?0.686及0.900?以BF最低值53.64 mL/(100g·min)为阈值鉴别早期肝癌组肿瘤组织与健康对照组肝组织,敏感度、特异度、阳性预测值、阴性预测值和准确率分别为95.5%、70.0%、95.5%、70.0%和83.3%。结论 3.0T MR 3D-ASL技术能反映早期原发性肝癌与健康对照组肝脏血流灌注差异,有助于原发性肝癌早期诊断。     

Elevated Levels of Plasma Transforming Growth Factor-β in Patients with Hepatocellular Carcinoma

We measured the plasma transforming growth factor-β (TGF-β) concentration in 14 patients with human hepatocellular carcinoma (HCC) and 9 age-matched normal subjects using growth inhibition assay of mink lung epithelial cells. The calculated plasma TGF-β concentration in the patients with HCC was 28.6 ± 27.9 ng/ml (mean± SE), showing significant elevation compared with that in 9 normal subjects (5.3 ± 3.3 ng/ml, P<0.01). In three cases, we could measure plasma TGF-β levels before and after their treatment for HCC. The plasma TGF-β levels decreased from 59.0 to 18.2 ng/ml after hepatic resection in one case, and from 24.0 to 10.7 ng/ml and from 12.4 to 3.4 ng/ml after transhepatic arterial embolization in the other two cases. These data indicate that plasma TGF-β level is elevated in patients with HCC, probably due to release from HCC tissues.     

Some Mineral,trace Element and Heavy Metal Concentrations in Lung Cancer

Objective: We aimed to determine the relationship between some mineral, trace element and heavy metallevels in the patients of lung cancer by measuring serum levels of copper (Cu), lead (Pb), zinc (Zn), iron (Fe),cobalt (Co), cadmium (Cd), manganese (Mn), magnesium (Mg). Methods: A total of 50 lung cancer and humanhealth (30 lung cancer and 20 healthy human) were included in the study. Venous blood samples of each lungcancer were obtained, and serum Cu, Pb, Zn, Fe, Cd, Co, Mn, Mg levels were analysed by Atomic AbsorptionSpectrophotometer measurements. Results: Mg value measured in lung cancer group were lower than the controlgroup and this was statistically significant (P<0.01). Serum Cu level was significantly lower with lung cancercompared to healthy human (P<0.01). Pb level was significantly higher than those of controls (P<0.01). Theserum Zn level was significantly lower in serum of lung cancer group than controls (P<0.01). Serum Mn and Colevels were found increased in lung cancer group than controls (P<0.01). Cd value was higher in lung cancer butit was not statistically significant (p>0.01). The mean concentration of Fe in the serum of lung cancer patientswas higher than in the controls, but the difference was not significant (p>0.01). There was a positive correlationbetween Cd and Pb level, and between Mn and Fe levels in lung cancer. There was a negative correlation betweenCo and Zn levels of healthy human. There was a negative correlation between Co and Mg levels of lung cancer.Conclusions: Serum Cu, Pb, Zn, Fe, Mg, Co, Mn and Cd might be play a role in the patients of lung cancers.Zn may protective as potent lung cancer. In addition, it is suggested that low levels of zinc can induce thepathogenesis of lung cancer.